We recently caught up with David Spigel from the Sarah Cannon Research Institute/Tennessee Oncology (TN, USA) to learn about the CheckMate-153 data he presented at the ESMO Congress (8–12th September, Madrid, Spain). Data from this study demonstrated that in patients with previously treated advanced non-small cell lung cancer,superior progression-free survival was induced with continuous treatment with nivolumab until disease progression compared with a 1 year fixed duration treatment.
Spigel joined Sarah Cannon in 2003 and as chief scientific officer, he oversees all scientific aspects of Sarah Cannon’s clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research.
Spigel received his bachelor’s degree from Tulane University (LA, USA) in 1992, and medical degree from The University of Tennessee (TN, USA) in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center (IN, USA), he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute (MA, USA). He is board certified in medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.